BCAX vs BK · $1.51B cap vs P/E 17, rev $20.08B
Bicara Therapeutics Inc. Common Stock (BCAX) versus The Bank of New York Mellon Corporation (BK) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
BCAX does not have a complete income-statement cache yet.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
BCAX currently screens at market cap $1.51B. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Not investment advice. Open the BCAX and BK stock pages for the full models.
Not investment advice.